CPI Logo-Color.png
Constellation Pharmaceuticals Announces First-Quarter 2021 Financial Results and Provides Business Update
May 10, 2021 07:00 ET | Constellation Pharmaceuticals , Inc.
Dosing underway in the Phase 3 MANIFEST-2 clinical trialRecommended Phase 2 dose determined for CPI-0209 and first patient dosed in the Phase 2 expansion cohortsUpcoming data presentation at ASCO...
CPI Logo-Color.png
Constellation Pharmaceuticals to Host Conference Call to Discuss First Quarter 2021 Results
April 27, 2021 11:30 ET | Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel...
CPI Logo-Color.png
Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2020 Financial Results
February 24, 2021 07:00 ET | Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop...
CPI Logo-Color.png
Constellation Pharmaceuticals to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
February 19, 2021 16:00 ET | Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
CPI Logo-Color.png
Constellation Pharmaceuticals to Host Conference Call to Discuss Fourth Quarter 2020 Results
February 18, 2021 10:00 ET | Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop...